Leu-enkephalin: the body's own natural painkiller
A tiny peptide made in the brain, spinal cord, and gut that eases pain by activating the same system as morphine, but produced naturally by the body, not a drug.
A researcher, an agent, or an algorithm wrote down the sequence and picked a target to hit.
An AI model like OpenFold3 or AlphaFold built a 3D structure and scored how well it fits the binding site.
A second contributor repeated the computation on their own hardware and the scores matched.
Endogenous peptide — produced naturally and routinely synthesized for research
Fork this card to add platform evidence →
Endogenous peptide — receptor binding and activity established in published literature
Fork this card to add platform evidence →
What this is
Leu-enkephalin is one of the body's own painkillers — a tiny five-amino-acid peptide (Tyr-Gly-Gly-Phe-Leu, or YGGFL) made and released by neurons in the brain, spinal cord, and gut. It is part of the endogenous opioid family: the same broad signalling system that morphine and other opiate drugs plug into, but built by the body itself. Leu-enkephalin and its sibling Met-enkephalin (/card/pep-04455, YGGFM) were the first endogenous opioids ever found, discovered in 1975 by John Hughes and Hans Kosterlitz at the University of Aberdeen — a finding that proved the brain makes its own morphine-like signal and reshaped the way pharmacologists thought about pain, mood, and addiction (Hughes, Smith, Kosterlitz and colleagues, Nature 1975).
Both pentapeptides come from a precursor protein called proenkephalin (PENK). When PENK is processed, roughly four copies of Met-enkephalin are released for every one copy of Leu-enkephalin (Clynen and colleagues, Mol Neurobiol 2014; reviewed in Roques and colleagues, Eur J Biochem 1996).
History
In the early 1970s it was already known that morphine acts on specific binding sites in the brain — but no one had isolated what those sites were "made for." In 1975 Hughes, Smith and Kosterlitz purified two short peptides from pig brain that suppressed electrically evoked contractions of the guinea-pig ileum and mouse vas deferens in a naloxone-reversible way (the standard opiate bioassays of the era). Sequencing by the dansyl–Edman procedure and mass spectrometry identified them as YGGFM and YGGFL — differing only in their last residue. The paper appeared in Nature under the title "Identification of two related pentapeptides from the brain with potent opiate agonist activity" (Hughes and colleagues 1975, Nature 258:577–579).
Within a few years the enkephalins were joined by β-endorphin and the dynorphins to form the three classical endogenous opioid families, each derived from its own precursor gene (POMC, PENK, PDYN). Comparative work has since traced the opioid system back through vertebrate evolution: a recent transcriptome and genome study of the Pacific hagfish Eptatretus stoutii identified a proenkephalin-like protein carrying Met-enkephalin (YGGFM) motifs nested within canonical dibasic cleavage sites, but no Leu-enkephalin motif — suggesting the Met/Leu pairing seen in mammals arose after the jawless-fish lineage split (Huang and colleagues, J Neurosci Res 2022).
A notable historical anecdote: Hughes and colleagues did not immediately notice that their YGGFM sequence was contained within β-lipotropin, a pituitary peptide whose sequence was already published. The connection was reportedly spotted by a colleague attending a London lecture on β-lipotropin — and it was that observation that linked pituitary peptide chemistry to the opioid system and led directly to β-endorphin (recounted in a historical review of opioid peptide neurobiology, Int Rev Neurobiol 1990).
What it does
Leu-enkephalin is a fast, short-acting neuromodulator. Released from enkephalinergic neurons, it binds δ-opioid receptors (and, with weaker affinity, µ-opioid receptors) on nearby cells and dampens neuronal firing. The behavioural and physiological effects most strongly tied to native enkephalin signalling are analgesia (reduced pain perception), modulation of mood and stress responses, contribution to gut motility, and — in the heart — a role in the cardioprotection that follows brief, repeated episodes of ischemia (so-called ischemic preconditioning) (reviewed in Peart and Gross, Vasc Pharmacol 2005; Schultz, Pharmacol Ther 2007).
The native peptide is not used as a drug. Its plasma half-life is on the order of minutes because at least three enzymes attack it rapidly: aminopeptidase N cleaves the N-terminal Tyr-Gly bond; the membrane metalloendopeptidase neprilysin (historically called "enkephalinase") cleaves the Gly³–Phe⁴ bond; and angiotensin-converting enzyme contributes in plasma. In human plasma specifically, aminopeptidase M and ACE together account for roughly 85–90 % of Leu-enkephalin hydrolysis (Shibanoki and colleagues, Neurochem Res 1991). This is one reason native enkephalins are studied as endogenous signalling molecules rather than as systemic therapeutics — and why much of the chemistry around them has focused on stabilised analogs (Ding and colleagues, Amino Acids 2020).
Mechanism
The δ-opioid receptor (DOR; gene OPRD1) is a class A G protein–coupled receptor coupled to inhibitory Gαi/o proteins. On binding Leu-enkephalin, the receptor activates Gαi/o, which lowers intracellular cAMP, opens G-protein-coupled inwardly rectifying potassium (GIRK) channels, and inhibits voltage-gated Ca²⁺ channels. The net effect is to hyperpolarise the neuron and reduce neurotransmitter release. δ-receptor activation can also recruit β-arrestin and engage MAPK signalling; the balance between G-protein and β-arrestin output is an active area for biased-agonist design (Vasudevan and colleagues, Sci Rep 2020, on meta-substitution of Phe⁴ as a signalling-bias handle).
The structural basis for δ-receptor recognition was established by the 3.4 Å crystal structure of the mouse δ-opioid receptor bound to the selective antagonist naltrindole (Granier, Manglik, Kruse and colleagues, Nature 2012; PDB 4EJ4). Active-state δ-receptor structures with peptide and small-molecule agonists were subsequently solved (Claff and colleagues, Sci Adv 2019), and a cryo-EM structure of an agonist-bound δ-receptor–Gi complex has been reported more recently (Nat Commun 2024).
Across the endogenous opioid peptide family the N-terminal tetrapeptide YGGF is the "message" sequence — the part that engages the receptor binding pocket — while the C-terminal residue or extension is the "address" that tunes which opioid receptor subtype the peptide prefers and how fast it is cleared. Replacing Gly² with D-alanine and Leu⁵ with D-leucine yields DADLE ([D-Ala²,D-Leu⁵]-enkephalin), a hydrolysis-resistant, δ-selective agonist that has become one of the standard pharmacological tools for probing DOR biology and that has shown neuroprotective and cardioprotective effects in preclinical hypoxic/ischemic models (Borlongan and colleagues 2009, reviewed in subsequent DOR neuroprotection literature). This D-amino-acid stabilisation strategy is one of the canonical examples of how introducing non-proteinogenic residues can transform a fragile endogenous peptide into a usable pharmacological probe (Ding and colleagues, Amino Acids 2020).
Evidence
- Human: Leu-enkephalin itself has not been developed as a clinical drug — its plasma half-life of a few minutes rules out conventional systemic use of the bare peptide. Clinical work on the enkephalin system has instead used either the longer Met-enkephalin (clinically studied in oncology as "opioid growth factor"; reviewed in Tian and colleagues, Int Immunopharmacol 2016) or enkephalinase inhibitors that prolong endogenous enkephalin signalling. Altered enkephalin immunoreactivity has been reported in human brain tissue in temporal lobe epilepsy, with the system discussed as a target for anticonvulsant drug development (Clynen and colleagues, Mol Neurobiol 2014).
- Animal: Native Leu-enkephalin and its protease-stable analog DADLE produce dose-dependent antinociception in rodents and, when given before ischemia, reduce infarct size in isolated heart preparations through a δ-opioid receptor mechanism (Schultz, Pharmacol Ther 2007; Peart and Gross, Vasc Pharmacol 2005). Comparative neuropeptidomic work has detected and quantified Leu-enkephalin across mammals — for example, by integrated mass spectrometry in the tree shrew (Tupaia belangeri) neuropeptidome (Petruzziello and colleagues, J Proteome Res 2012).
- In vitro: Leu-enkephalin depresses electrically evoked contractions of the guinea-pig ileum and mouse vas deferens with potencies in the low- to mid-nanomolar range, and the effect is fully reversed by naloxone — the classical bioassay that defines an opioid agonist (Broccardo and colleagues, Br J Pharmacol 1981, the dermorphin comparison study, in which Leu-enkephalin was used as a reference). Recent SAR work using cAMP and β-arrestin recruitment assays has refined δ- and µ-opioid receptor pharmacology of Leu-enkephalin analogs and characterised signalling bias (Vasudevan and colleagues, Sci Rep 2020). Leu-enkephalin is also widely used as a benchmark small peptide for new synthetic chemistry — e.g., aqueous solid-phase peptide synthesis of Leu-enkephalin amide as a short-chain model peptide (RSC Adv 2016), and as a substrate for combinatorial-library chemistry (Ostresh and colleagues, PNAS 1994).
Known effects
- Antinociception — Mechanistic and preclinical in native peptide; pharmacologically defined as a δ-opioid receptor effect.
- Cardioprotection during ischemia–reperfusion — Preclinical (rodent and rabbit isolated-heart models); δ-opioid receptor–dependent (Peart and Gross 2005).
- Modulation of seizure circuits — Preclinical and human postmortem data link enkephalin levels and proenkephalin-A processing to temporal lobe epilepsy and rodent seizure models (Clynen 2014).
- Modulation of gut motility — Mechanistic; the guinea-pig ileum bioassay is the classical readout, reflecting δ- and µ-receptor expression on enteric neurons.
- Reference substrate for enkephalin-degrading enzymes — Used pharmacologically to characterise aminopeptidase N, neprilysin, and ACE activity, and to probe the mechanism of the Russian heptapeptide Selank (/card/pep-00006), one mode of action of which is inhibition of plasma enkephalin-degrading enzymes (Zolotarev and colleagues, as cited in Bull Exp Biol Med 2016/2019).
Safety signals
Native Leu-enkephalin is an endogenous neuromodulator and is not an approved drug, so it has no FDA label or EMA EPAR with a structured adverse-event profile. As a class, δ- and µ-opioid receptor activation carries the general liabilities of opioid signalling (sedation, respiratory depression at high agonism, tolerance with repeated exposure); δ-receptor agonism specifically has been associated with seizure liability in some preclinical small-molecule agonist programs (reviewed in the DOR drug-development literature). Specific human safety data for the bare pentapeptide are not available because no clinical product based on it exists.
Regulatory status
- US: No FDA-approved product. Leu-enkephalin is studied as an endogenous peptide and as a scaffold for opioid analog design.
- EU: No EMA-approved product based on native Leu-enkephalin.
- WADA: Endogenous opioid peptides are not named individually on the current Prohibited List. Exogenous narcotic analgesics are restricted in-competition (class S7); the status of any future stabilised δ-opioid peptide agonist would be considered under that framework.
Related peptides
- Met-enkephalin (/card/pep-04455) — sibling pentapeptide YGGFM from the same PENK precursor; produced in ~4:1 excess over Leu-enkephalin. Clinically studied in oncology as "opioid growth factor" (Tian 2016).
- Dynorphin A (1-17) (/card/pep-10704) — YGGFLRRIRPKLKWDNQ; the long-form prodynorphin product, which begins with the Leu-enkephalin sequence but is κ-receptor-selective due to its basic C-terminal extension.
- Dynorphin A (1-8) (/card/pep-10699) — YGGFLRRI; the shortest naturally occurring dynorphin.
- Nociceptin / Orphanin FQ (/card/pep-10535) — FGGFTGARKSARKLANQ; the fourth-family endogenous opioid-like peptide, ligand for the nociceptin receptor (NOP, OPRL1).
- Selank (/card/pep-00006) — synthetic heptapeptide; one published mechanism is inhibition of plasma enkephalin-degrading enzymes, prolonging endogenous Leu-enkephalin signalling.
Open questions
- Whether a biased δ-opioid agonist preserving Leu-enkephalin's analgesic/antidepressant signal while avoiding seizure liability and tolerance can be designed clinically — only partially answered by the meta-Phe⁴ SAR work (Vasudevan 2020).
- The functional contribution of native Leu-enkephalin (vs Met-enkephalin and dynorphins) to specific human physiology is hard to dissect because PENK produces both pentapeptides simultaneously.
- Whether the cardioprotective effect of δ-opioid receptor activation in preclinical models translates into clinically meaningful infarct-size reduction in humans remains unresolved.
Research directions for this peptide, selected from the current sources — hypotheses you can explore and model. None of it is proven yet; tap any one to see the full thinking.
Could the body's own Leu-enkephalin, acting in the gut rather than the brain, help control the inflammation seen in conditions like Crohn's disease?
If true, gut-targeted enkephalin analogs could offer a new approach to inflammatory bowel disease that works through the body's own pain-and-calm circuitry, potentially with fewer central nervous system side effects than existing therapies, helping millions of patients with chronic gut inflammation.
If you chemically mask the key oxygen atom on the first amino acid of Leu-enkephalin, does it stop activating the receptor and instead block it?
If true, this one-atom switch would give researchers a simple way to create both activators and blockers of the delta pain receptor from the same natural template. Receptor blockers could be useful for reversing opioid tolerance or treating mood disorders linked to the opioid system.
If the ends of Leu-enkephalin are close enough together when it binds its receptor, could fusing them into a ring create a longer-lasting version that still targets the right receptor?
If true, a ring-shaped version of Leu-enkephalin would survive in the body far longer than the natural peptide, which breaks down in seconds. This could lead to a non-addictive, naturally inspired pain drug without the need for large, expensive molecules.
Does Leu-enkephalin, by virtue of its flexible shape, naturally favor the 'good' painkilling signal over the 'bad' tolerance-causing signal inside nerve cells?
If true, it would mean the human body already produces a safer opioid signal by design. Drugs engineered to copy this behavior could relieve pain without generating the tolerance and dependence that plague current opioid medicines.
▸full evidence table2 metrics
| metric | value | tool |
|---|---|---|
| ipTM | 0.9673482775688171 | boltz-2 |
| ranking score | 0.8517279624938965 | boltz-2 |
▸structural qualityopenfold3
| metric | value | note |
|---|---|---|
| gpde | 0.717 | global PDE — lower = better |
| disorder | NaN | fraction disordered |
▸3-letter notation
▸recipeboltz-2 1.0
| parameter | value |
|---|---|
| model | boltz-2 1.0 |
| weights | — |
| hardware | nvidia_nim_api |
| mlx version | — |
| python | — |
| random seed | — |
| msa strategy | none |
| diffusion samples | 1 |
| runtime | — |
| predicted by | mlx@peptide |
| predicted at | 2026-04-24 |
▸citationbibtex
@peptide{pep04456,
sequence = {YGGFL},
target = {oprd1},
author = {peptidemodel},
year = {2026},
status = {bioassayed}
}